Fig. 2.
Pharmacological intervention prior to neurofibroma formation. a Plasma concentration of PLX3397 in Dhh-Cre; Nf1flox/flox mice over time. b Experimental design. c Fur pigmentation loss in mice receiving PLX3397 (lower panel) and not in control mice (upper panel). d MRI shows increase in volume of neurofibromas treated with PLX3397. Images are from representative tumor-bearing mice given vehicle control (left) and PLX3397 (right). e Volumetric measurement. f PLX3397 treatment induced mast cell and macrophage depletion in neurofibromas. Toluidine blue staining (red arrows) indicates detection of mast cells and brown staining indicates detection of Iba1+ cells in paraffin sections from control and PLX3397-treated Dhh-Cre; Nf1flox/flox mouse neurofibromas. g Remak bundle disruption was not prevented by treatment with PLX3397. Electron microscope photographs (×12,000) from sciatic nerve. h Graphs show average cell counts for Iba1+ cells (*p < 0.001), and toluidine blue cells (*p < 0.01) per high-powered field in control (n = 6) and PLX3397 (n = 6) treated neurofibromas